Skip to main content

5 articles related to "Gz17 602"

No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.

Articles

Original Research

Published on 03 Nov 2022

GZ17-6.02 kills prostate cancer cells in vitro and in vivo

in Cancer Molecular Targets and Therapeutics

Laurence Booth
Jane L. Roberts
Cameron West
Paul Dent

Frontiers in Oncology

doi 10.3389/fonc.2022.1045459

3,553 views
8 citations

Original Research

Published on 08 Apr 2021

GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells

in Cancer Molecular Targets and Therapeutics

Laurence Booth
Cameron West
Daniel Von Hoff
John M. Kirkwood
Paul Dent

Frontiers in Oncology

doi 10.3389/fonc.2021.656453

5,770 views
15 citations

Original Research

Published on 19 Aug 2021

GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins

in Cancer Molecular Targets and Therapeutics

Laurence Booth
Cameron West
Robert P. Moore
Daniel Von Hoff
Paul Dent

Frontiers in Oncology

doi 10.3389/fonc.2021.711043

5,764 views
15 citations

Correction

Published on 16 Apr 2021

Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

in Cancer Molecular Targets and Therapeutics

Laurence Booth
Cameron West
Daniel Von Hoff
Paul Dent

Frontiers in Oncology

doi 10.3389/fonc.2021.677725

1,573 views
1 citation

Original Research

Published on 02 Sep 2020

GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

in Cancer Molecular Targets and Therapeutics

Laurence Booth
Cameron West
Daniel Von Hoff
Paul Dent

Frontiers in Oncology

doi 10.3389/fonc.2020.01331

3,873 views
13 citations